Articles Tập 67 Số CĐ14-HNKH Hội Hóa sinh Y học Việt Nam 19/09/2026

DETECTION OF ALK, ROS1, RET GENE FUSIONS AND MET EXON 14 SKIPPING MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AT NINH BINH PROVINCIAL GENERAL HOSPITAL.

Tran Khanh Chi, Vu Thi Huyen Trang, Nguyen Hoang Yen, Trieu Thi Phương Mai, Tran Minh Huong, Trinh Hung Son, Le Minh Hang, Bui Thi Duyen, Nguyen Le Hung, Le Hoan, Dang Thi Ngoc Dung
DOI: 10.52163/yhc.v67iCD14.6479
0 Views
0 Downloads
Abstract

Objectives: 1) To evaluate the rate of ALK, ROS1, RET gene fusions and MET exon 14 skipping mutations in patients with non-small cell lung cancer at Ninh Binh Provincial General Hospital. 2) To assess the relationship between ALK, ROS1, RET gene fusions, MET exon 14 skipping mutations and pathological characteristics in non-small-cell lung cancer.

Methods: A cross-sectional descriptive study was conducted on 206 patients with non-small cell lung cancer at Ninh Binh General Hospital from 2023 to 2026. Real-time RT-PCR method was utilized to identify ALK, ROS1, and RET gene fusions, as well as MET exon 14 skipping mutations.

Results: We found the prevalence of ALK, ROS1, RET gene fusions and MET exon 14 skipping mutations was 4.9%, 0%, 0.5% and 0.5%, respectively. ALK gene fusion was more commonly detected in female, non-smokers. We did not observe any statistically significant association between age or histopathological results and the ALK fusion. Regarding the ROS1 and RET gene fusions and the MET exon 14 skipping mutations, due to their very low detection rates, the study did not have sufficient basis to statistically analyze the correlations between these alterations and clinical or subclinical characteristics.

Conclusions: ALK, ROS1 and RET gene fusions and MET exon 14 skipping mutations are rare genetic alterations in patients with non-small cell lung cancer. ALK gene fusion was more commonly detected in female, non-smokers.

Keywords
Non-small cell lung cancer, gene fusion, Ninh Binh.
References
[1]
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229–63. doi:10.3322/caac.21834 Google Scholar
[2]
2. Lee JB, Shim JS, Cho BC. Evolving roles of MET as a therapeutic target in NSCLC and beyond. Nat Rev Clin Oncol. 2025 Sep;22(9):640–66. doi:10.1038/s41571-025-01051-9 Google Scholar
[3]
3. Rosas D, Jones C, Akinbobuyi O, Theik Y, Alvarez-Pinzon A, Raez L. Molecular Targeting in Non-Small Cell Lung Cancer: Advances in EGFR, ROS1, ALK, and MET Pathways. Journal of Oncology Research and Therapy. 2024 Jan 1;10214. Google Scholar
[4]
4. Chung EK, Yong SH, Lee EH, Kim EY, Chang YS, Lee SH. New Targeted Therapy for Non-Small Cell Lung Cancer. Vol. 86. 2023;86(1). doi: 10.4046/trd.2022.0066 Google Scholar
[5]
5. Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol. 2022 May;17(5):608–22. doi:10.1016/j.jtho.2021.12.014 Google Scholar
[6]
6. Sharma S, Noronha V, Yadav A, Mandhania M, Mohanty SK, Katara R, et al. Comprehensive Genomic Profiling of Indian Patients With Lung Cancer. JCO Glob Oncol. 2025 May;(11):e2400587. doi:10.1200/GO-24-00587 Google Scholar
[7]
7. Hardtstock F, Myers D, Li T, Cizova D, Maywald U, Wilke T, et al. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis. BMC Cancer. 2020 Mar 30;20:260. doi:10.1186/s12885-020-06738-z Google Scholar
[8]
8. Huỳnh Quang Huy. Nghiên cứu đặc điểm bệnh nhân và mô bệnh học ung thư phổi không tế bào nhỏ. Tạp chí Y học Việt Nam. 2025;548(3):374–6. Google Scholar
[9]
9. Li D, Ding L, Ran W, Huang Y, Li G, Wang C, et al. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution. Thorac Cancer. 2020 Sep;11(9):2580–9. doi:10.1111/1759-7714.13577 Google Scholar
[10]
10. Linh Dieu Vuong, Quang Ngoc Nguyen. Oncogenic driver mutations in Vietnamese patients with lung adenocarcinoma. JABET. 2023;6(2):412–8. Google Scholar
[11]
11. Dương Thị Thùy Linh, Lê Hoàn. Xác định tỷ lệ dung hợp gen EML4-ALK và mối liên quan với một số đặc điểm lâm sàng và giải phẫu bệnh ở người bệnh ung thư phổi không tế bào nhỏ. Tạp chí Y học Việt Nam. 2023;522(2):268–71. Google Scholar
[12]
12. Paik JH, Choi CM, Kim H, Jang SJ, Choe G. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer. 2012 Jun 1;76(3):403–9. doi:10.1016/j.lungcan.2011.11.008 Google Scholar
[13]
13. Fan L, Feng Y, Wan H, Shi G, Niu W. Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review and Meta-Analysis. PLOS ONE. 2014 thg 6;9(6):e100866. doi:10.1371/journal.pone.0100866 Google Scholar